Views & Analysis ASH 2017: CAR-T therapy and beyond As the American Society of Hematology’s 2017 congress approaches, there’s plenty to be excited about – not just in blood cancer, but in previously overlooked diseases such as sickle cell anaemi
News J&J rumoured to be sizing up $12bn Genmab acquisition Speculation mounts that J&J will bid for R&D partner
News Future uncertain for Innate and BMS' troubled lirilumab Doubts over future of cancer immunotherapy
News FDA approvals expand reach of Roche's Zelboraf and Alecensa New US indications for Zelboraf and Alecensa
News Novartis files CAR-T in Europe in broader use than Gilead ri... Swiss pharma chasing EU licence in NHL and ALL indications
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
